Outcomes following subcutaneous and intravenous treatment with lecanemab for Alzheimer’s disease were comparable, according ...
Gov. Bill Lee refuses to review Tennessee's lethal injection protocol after a failed execution attempt.
BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today presented new data at the 2026 Alzheimer's Association ...
Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced today that new data presented at the Alzheimer’s Association International Conference ® (AAIC ®) 2026 in London support that the LEQEMBI ® ...
The U.S. Food and Drug Administration said on Friday it has approved a wearable form of Sanofi's blood cancer drug, ...
New clinical and real-world data support a subcutaneous treatment pathway from initiation through maintenance treatment, offering dosing convenience for patients and ...
Sanofi (SNY) wins FDA approval for Sarclisa Escena, a subcutaneously-delivered version of its multiple myeloma therapy ...
Sanofi’s subcutaneous Sarclisa Escena approved in the US as first anticancer treatment administered via on-body injector Sarclisa Escena ...
Bryan Johnson revealed his Autoimmune Gastritis diagnosis, which he believes sparked global negative reactions. He suggests ...
Sanofi has scored FDA approval for its subcutaneous version of Sarclisa, giving the multiple myeloma treatment a potential ...
It’s unlikely Gov. Bill Lee will call a death penalty moratorium before Tennessee’s next execution. Calls for a temporary ...
Regulatory clearance adds a 1,400-mg subcutaneous CD38 antibody option using CirCLIQ on-body delivery or provider-administered injection, maintaining the same active medicine as the IV formulation.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results